Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials - PubMed (original) (raw)

Review

Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Dario Giugliano et al. Endocrine. 2016 Mar.

Abstract

The purpose of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effect of intensified insulin regimens (basal-bolus versus premixed) on glycemic control in patients with type 2 diabetes. We conducted an electronic search until March 2015 on many electronic databases including online registries of ongoing trials. All RCTs comparing basal-bolus with premixed insulin regimens, with a duration of >12 weeks and with >30 patients per arm, were included. Investigators extracted data on study characteristics, outcome measures, and methodological quality. We found thirteen RCTs lasting 16-60 weeks and involving 5255 patients assessed for the primary endpoint (reduction of HbA1c from baseline). Meta-analysis of change in HbA1c level between basal-bolus and premixed insulin regimens resulted in a small and non-significant difference of 0.09% (95% CI -0.03 to 0.21), with substantial heterogeneity between studies (I(2) = 74.4%). There was no statistically significant difference in the event rate for overall hypoglycemia (0.16 episode/patient/year, 95%CI -2.07 to 2.3), weight change (-0.21 kg, -0.164 to 0.185), and daily insulin dose (-0.54 U/day, -2.7 to 1.6). The likelihood for reaching the HbA1c <7% was 8% higher (3-13%, I(2) = 68.8%) with the basal-bolus as compared with the premixed regimen. There is no clinically relevant difference in the efficacy of basal-bolus versus premixed insulin regimens for HbA1c decrease in type 2 diabetic patients. These findings may be helpful to adapt treatment to individual patient needs.

Keywords: Basal-bolus; Insulin regimens; Meta-analysis; Premix; Type 2 diabetes.

PubMed Disclaimer

Similar articles

• Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?
  Giugliano D, Sieradzki J, Stefanski A, Gentilella R. Giugliano D, et al. Curr Med Res Opin. 2016 Aug;32(8):1425-34. doi: 10.1080/03007995.2016.1181051. Epub 2016 May 25. Curr Med Res Opin. 2016. PMID: 27126277 Review.
• Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data.
  Anyanwagu U, Mamza J, Gordon J, Donnelly R, Idris I. Anyanwagu U, et al. Diabet Med. 2017 Dec;34(12):1728-1736. doi: 10.1111/dme.13518. Epub 2017 Oct 14. Diabet Med. 2017. PMID: 28945928
• Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
  Jia W, Xiao X, Ji Q, Ahn KJ, Chuang LM, Bao Y, Pang C, Chen L, Gao F, Tu Y, Li P, Yang J. Jia W, et al. Lancet Diabetes Endocrinol. 2015 Apr;3(4):254-62. doi: 10.1016/S2213-8587(15)00041-8. Epub 2015 Mar 6. Lancet Diabetes Endocrinol. 2015. PMID: 25754414 Clinical Trial.
• Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
  Ilag LL, Kerr L, Malone JK, Tan MH. Ilag LL, et al. Clin Ther. 2007 Jun;29(6 Pt 1):1254-70. doi: 10.1016/j.clinthera.2007.07.003. Clin Ther. 2007. PMID: 18036388 Review.

Cited by

• Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges.
  Emad-Eldin M, Balata GF, Elshorbagy EA, Hamed MS, Attia MS. Emad-Eldin M, et al. World J Diabetes. 2024 May 15;15(5):828-852. doi: 10.4239/wjd.v15.i5.828. World J Diabetes. 2024. PMID: 38766443 Free PMC article. Review.
• 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2023.
  ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. ElSayed NA, et al. Diabetes Care. 2023 Jan 1;46(Suppl 1):S267-S278. doi: 10.2337/dc23-S016. Diabetes Care. 2023. PMID: 36507644 Free PMC article. Review.
• Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.
  Jude EB, Malecki MT, Gomez Huelgas R, Prazny M, Snoek F, Tankova T, Giugliano D, Khunti K. Jude EB, et al. Diabetes Ther. 2022 Apr;13(4):619-634. doi: 10.1007/s13300-022-01222-2. Epub 2022 Mar 11. Diabetes Ther. 2022. PMID: 35274219 Free PMC article. Review.
• Reporting and methodological quality of systematic reviews and meta-analysis with protocols in Diabetes Mellitus Type II: A systematic review.
  Rainkie DC, Abedini ZS, Abdelkader NN. Rainkie DC, et al. PLoS One. 2020 Dec 16;15(12):e0243091. doi: 10.1371/journal.pone.0243091. eCollection 2020. PLoS One. 2020. PMID: 33326429 Free PMC article.

References

1. 1. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):511-9 - PubMed
2. 1. Endocrine. 2015 Sep;50(1):56-60 - PubMed
3. 1. Diabetes Obes Metab. 2010 Feb;12(2):115-23 - PubMed
4. 1. N Engl J Med. 2009 Oct 29;361(18):1736-47 - PubMed
5. 1. Diabetes Obes Metab. 2009 Jan;11(1):45-52 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information